Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 30 to 75

Intranasal oxytocin to help with pain after pituitary surgery

Official title: Investigating the Effect of TNX-1900 on Pain Management, Neural and Socio-Emotional Functioning in Patients Undergoing Pituitary Surgery

Run by Yale University · NCT07730294 · Data updated 2026-11-12

This study tests whether intranasal oxytocin can reduce pain after pituitary surgery and improve recovery.

Quick facts

PhasePhase 2
Study typeInterventional
Ages30 Years to 75 Years
SexAll
Enrollment75 (estimated)
SponsorYale University
Academic / other
Locations1 site (New Haven, Connecticut)
StatusRecruiting
StartedNovember 2026
Main results expectedNovember 2028
Study endsNovember 2028
Registry record updatedNovember 6, 2026
Trial IDNCT07730294 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 30–75 undergoing pituitary surgery without recent changes in psychotropic medications and without exclusionary medical conditions.

Probably not a fit

Patients with seizure history, significant liver or kidney impairment, current pregnancy or recent postpartum period, or prior pituitary surgery may have limited or no benefit and could be excluded for safety.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 2 trial, adults undergoing pituitary surgery are randomly assigned to low-dose oxytocin, high-dose oxytocin, or placebo for seven days before and after surgery. The study uses a double-blind design to compare pain outcomes, neural measures, and socio-emotional health across groups. Researchers will collect surveys and EEG/ERP data to understand how oxytocin might influence pain processing and emotional aspects of recovery. Safety and tolerability will be monitored throughout the perioperative period.

Why it matters

Potential benefit: If successful, the treatment could provide another option to ease pain and improve recovery after pituitary surgery.

How similar studies have gone: Past studies in other settings have explored oxytocin for pain and emotional processing, with mixed results, making this approach exploratory in pituitary surgery.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: Between 30 to 75 years old.
* Consent: Ability to give informed consent.
* Language: Proficiency in the English language.
* Medical Condition: Diagnosed with a pituitary lesion requiring surgery.
* Menopausal Status: Post-menopause for women (at least 1 year since last menstrual period).

Exclusion Criteria:

* Medication: Individuals on stable doses of psychotropic medication for at least the past six weeks are eligible, excluding those with changes in medication within that timeframe.
* Neurological Conditions: A history of seizures, current use of anticonvulsants.
* Pregnancy: Currently pregnant, currently lactating, or up to 1-year post partum.
* Any history of renal impairment (serum creatinine \>1.2 x ULN)
* Any history of hepatic impairment (AST and/or ALT \>2 x ULN)
* Surgical History: Any history of previous pituitary surgery procedures
* Subjects who require 24-hour coverage with NSAIDs, e.g., arthritis, should not be included in the study.
* Any known hypersensitivity to TNX-1900

Where it's running

  • Yale University
    New Haven, Connecticut, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.